Changes in beta cell function during the proximate post-diagnosis period in persons with type 1 diabetes

Linda DiMeglio, Peiyao Cheng, Roy W. Beck, Craig Kollman, Katrina J. Ruedy, Robert Slover, Tandy Aye, Stuart A. Weinzimer, Andrew A. Bremer, Bruce Buckingham

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: Prior studies examining beta-cell preservation in type 1 diabetes have predominantly assessed stimulated C-peptide concentrations approximately 10 wk after diagnosis. We examined whether earlier assessments might aid in prediction of beta cell function over time. Methods: Using data from a multi-center randomized trial assessing the effect of intensive diabetes management initiated within 1 wk of diagnosis, we assessed which clinical factors predicted 90-min mixed-meal tolerance test (MMTT) stimulated C-peptide values obtained 2 and 6 wk after diagnosis. We also studied associations of these factors with C-peptide values at 1- and 2-year post-diagnosis. Data from intervention and control groups were pooled. Results: Among 67 study participants (mean age 13.3 ± 5.7 yr, range 7.8-45.7 yr) in multivariable analyses, C-peptide increased from baseline to 2 wks and then 6 wk. C-peptide levels at these times were significantly correlated with 1- and 2-yr C-peptide concentrations (all p <0.001), with the strongest observed associations between 6-wk C-peptide and the 1- and 2-yr values (r = 0.66 and r = 0.61, respectively). In multivariable analyses, greater baseline and 6-wk C-peptide, and older age independently predicted greater 1- and 2-yr C-peptide concentrations. Conclusions: C-peptide assessments close to diagnosis were predictive of subsequent C-peptide production. Our data demonstrate a clear increase in C-peptide over the initial 6 wk after diabetes diagnosis followed by a plateau. Our data do not suggest that MMTT assessments performed closer to diagnosis than 6 wk would improve prediction of subsequent residual beta cell function.

Original languageEnglish (US)
Pages (from-to)237-243
Number of pages7
JournalPediatric Diabetes
Volume17
Issue number4
DOIs
StatePublished - Jun 1 2016

Fingerprint

C-Peptide
Type 1 Diabetes Mellitus
Meals

Keywords

  • Clinical science
  • Diabetes in childhood
  • Insulin secretions in vivo

ASJC Scopus subject areas

  • Internal Medicine
  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism

Cite this

DiMeglio, L., Cheng, P., Beck, R. W., Kollman, C., Ruedy, K. J., Slover, R., ... Buckingham, B. (2016). Changes in beta cell function during the proximate post-diagnosis period in persons with type 1 diabetes. Pediatric Diabetes, 17(4), 237-243. https://doi.org/10.1111/pedi.12271

Changes in beta cell function during the proximate post-diagnosis period in persons with type 1 diabetes. / DiMeglio, Linda; Cheng, Peiyao; Beck, Roy W.; Kollman, Craig; Ruedy, Katrina J.; Slover, Robert; Aye, Tandy; Weinzimer, Stuart A.; Bremer, Andrew A.; Buckingham, Bruce.

In: Pediatric Diabetes, Vol. 17, No. 4, 01.06.2016, p. 237-243.

Research output: Contribution to journalArticle

DiMeglio, L, Cheng, P, Beck, RW, Kollman, C, Ruedy, KJ, Slover, R, Aye, T, Weinzimer, SA, Bremer, AA & Buckingham, B 2016, 'Changes in beta cell function during the proximate post-diagnosis period in persons with type 1 diabetes', Pediatric Diabetes, vol. 17, no. 4, pp. 237-243. https://doi.org/10.1111/pedi.12271
DiMeglio, Linda ; Cheng, Peiyao ; Beck, Roy W. ; Kollman, Craig ; Ruedy, Katrina J. ; Slover, Robert ; Aye, Tandy ; Weinzimer, Stuart A. ; Bremer, Andrew A. ; Buckingham, Bruce. / Changes in beta cell function during the proximate post-diagnosis period in persons with type 1 diabetes. In: Pediatric Diabetes. 2016 ; Vol. 17, No. 4. pp. 237-243.
@article{5c8baaa06c6b44c3ad5e8949297daa81,
title = "Changes in beta cell function during the proximate post-diagnosis period in persons with type 1 diabetes",
abstract = "Objective: Prior studies examining beta-cell preservation in type 1 diabetes have predominantly assessed stimulated C-peptide concentrations approximately 10 wk after diagnosis. We examined whether earlier assessments might aid in prediction of beta cell function over time. Methods: Using data from a multi-center randomized trial assessing the effect of intensive diabetes management initiated within 1 wk of diagnosis, we assessed which clinical factors predicted 90-min mixed-meal tolerance test (MMTT) stimulated C-peptide values obtained 2 and 6 wk after diagnosis. We also studied associations of these factors with C-peptide values at 1- and 2-year post-diagnosis. Data from intervention and control groups were pooled. Results: Among 67 study participants (mean age 13.3 ± 5.7 yr, range 7.8-45.7 yr) in multivariable analyses, C-peptide increased from baseline to 2 wks and then 6 wk. C-peptide levels at these times were significantly correlated with 1- and 2-yr C-peptide concentrations (all p <0.001), with the strongest observed associations between 6-wk C-peptide and the 1- and 2-yr values (r = 0.66 and r = 0.61, respectively). In multivariable analyses, greater baseline and 6-wk C-peptide, and older age independently predicted greater 1- and 2-yr C-peptide concentrations. Conclusions: C-peptide assessments close to diagnosis were predictive of subsequent C-peptide production. Our data demonstrate a clear increase in C-peptide over the initial 6 wk after diabetes diagnosis followed by a plateau. Our data do not suggest that MMTT assessments performed closer to diagnosis than 6 wk would improve prediction of subsequent residual beta cell function.",
keywords = "Clinical science, Diabetes in childhood, Insulin secretions in vivo",
author = "Linda DiMeglio and Peiyao Cheng and Beck, {Roy W.} and Craig Kollman and Ruedy, {Katrina J.} and Robert Slover and Tandy Aye and Weinzimer, {Stuart A.} and Bremer, {Andrew A.} and Bruce Buckingham",
year = "2016",
month = "6",
day = "1",
doi = "10.1111/pedi.12271",
language = "English (US)",
volume = "17",
pages = "237--243",
journal = "Pediatric Diabetes",
issn = "1399-543X",
publisher = "Blackwell Munksgaard",
number = "4",

}

TY - JOUR

T1 - Changes in beta cell function during the proximate post-diagnosis period in persons with type 1 diabetes

AU - DiMeglio, Linda

AU - Cheng, Peiyao

AU - Beck, Roy W.

AU - Kollman, Craig

AU - Ruedy, Katrina J.

AU - Slover, Robert

AU - Aye, Tandy

AU - Weinzimer, Stuart A.

AU - Bremer, Andrew A.

AU - Buckingham, Bruce

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Objective: Prior studies examining beta-cell preservation in type 1 diabetes have predominantly assessed stimulated C-peptide concentrations approximately 10 wk after diagnosis. We examined whether earlier assessments might aid in prediction of beta cell function over time. Methods: Using data from a multi-center randomized trial assessing the effect of intensive diabetes management initiated within 1 wk of diagnosis, we assessed which clinical factors predicted 90-min mixed-meal tolerance test (MMTT) stimulated C-peptide values obtained 2 and 6 wk after diagnosis. We also studied associations of these factors with C-peptide values at 1- and 2-year post-diagnosis. Data from intervention and control groups were pooled. Results: Among 67 study participants (mean age 13.3 ± 5.7 yr, range 7.8-45.7 yr) in multivariable analyses, C-peptide increased from baseline to 2 wks and then 6 wk. C-peptide levels at these times were significantly correlated with 1- and 2-yr C-peptide concentrations (all p <0.001), with the strongest observed associations between 6-wk C-peptide and the 1- and 2-yr values (r = 0.66 and r = 0.61, respectively). In multivariable analyses, greater baseline and 6-wk C-peptide, and older age independently predicted greater 1- and 2-yr C-peptide concentrations. Conclusions: C-peptide assessments close to diagnosis were predictive of subsequent C-peptide production. Our data demonstrate a clear increase in C-peptide over the initial 6 wk after diabetes diagnosis followed by a plateau. Our data do not suggest that MMTT assessments performed closer to diagnosis than 6 wk would improve prediction of subsequent residual beta cell function.

AB - Objective: Prior studies examining beta-cell preservation in type 1 diabetes have predominantly assessed stimulated C-peptide concentrations approximately 10 wk after diagnosis. We examined whether earlier assessments might aid in prediction of beta cell function over time. Methods: Using data from a multi-center randomized trial assessing the effect of intensive diabetes management initiated within 1 wk of diagnosis, we assessed which clinical factors predicted 90-min mixed-meal tolerance test (MMTT) stimulated C-peptide values obtained 2 and 6 wk after diagnosis. We also studied associations of these factors with C-peptide values at 1- and 2-year post-diagnosis. Data from intervention and control groups were pooled. Results: Among 67 study participants (mean age 13.3 ± 5.7 yr, range 7.8-45.7 yr) in multivariable analyses, C-peptide increased from baseline to 2 wks and then 6 wk. C-peptide levels at these times were significantly correlated with 1- and 2-yr C-peptide concentrations (all p <0.001), with the strongest observed associations between 6-wk C-peptide and the 1- and 2-yr values (r = 0.66 and r = 0.61, respectively). In multivariable analyses, greater baseline and 6-wk C-peptide, and older age independently predicted greater 1- and 2-yr C-peptide concentrations. Conclusions: C-peptide assessments close to diagnosis were predictive of subsequent C-peptide production. Our data demonstrate a clear increase in C-peptide over the initial 6 wk after diabetes diagnosis followed by a plateau. Our data do not suggest that MMTT assessments performed closer to diagnosis than 6 wk would improve prediction of subsequent residual beta cell function.

KW - Clinical science

KW - Diabetes in childhood

KW - Insulin secretions in vivo

UR - http://www.scopus.com/inward/record.url?scp=84969822556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969822556&partnerID=8YFLogxK

U2 - 10.1111/pedi.12271

DO - 10.1111/pedi.12271

M3 - Article

C2 - 25720763

AN - SCOPUS:84969822556

VL - 17

SP - 237

EP - 243

JO - Pediatric Diabetes

JF - Pediatric Diabetes

SN - 1399-543X

IS - 4

ER -